Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial blockade at the level of p21 is associated with short response duration

Ke Lin, Janet Adamson, Gillian G Johnson, Anthony Carter, Melanie Oates, Rachel Wade, Sue Richards, David Gonzalez, Estella Matutes, Claire Dearden, David G Oscier, Daniel Catovsky, Andrew R Pettitt

Research output: Contribution to journalArticle

25 Citations (Scopus)


This study sought to establish whether functional analysis of the ATM-p53-p21 pathway adds to the information provided by currently available prognostic factors in patients with chronic lymphocytic leukemia (CLL) requiring frontline chemotherapy.
Original languageEnglish
Pages (from-to)4191-200
Number of pages10
JournalClinical Cancer Research : An Official Journal of the American Association for Cancer Research
Issue number15
Publication statusPublished - 1 Aug 2012



  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Ataxia Telangiectasia Mutated Proteins
  • Cell Cycle Proteins
  • Chlorambucil
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclophosphamide
  • DNA-Binding Proteins
  • Female
  • Flow Cytometry
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukocytes, Mononuclear
  • Male
  • Middle Aged
  • Mutation
  • Prognosis
  • Protein-Serine-Threonine Kinases
  • Randomized Controlled Trials as Topic
  • Signal Transduction
  • Survival Analysis
  • Tumor Suppressor Protein p53
  • Tumor Suppressor Proteins
  • Vidarabine

Cite this